Acaluxen 100mg Capsule (Acalabrutinib)

Acaluxen 100mg Capsule is a prescription-based anticancer medicine used in the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL), and small lymphocytic lymphoma (SLL). The active ingredient of Acaluxen is acalabrutinib, which belongs to the drug class of Bruton's tyrosine kinase (BTK) inhibitors. It works by blocking the BTK protein, which helps in the growth and replication of abnormal B cells. This action can decrease cancer progression and cancer load. Acalabrutinib 100mg Capsule is used as monotherapy and in combination with another anticancer medicine as a part of combination therapy to increase the efficacy of the treatment.

The capsule must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the Acalabrutinib 100mg Capsule depend on the patient's condition and response to treatment. It can also be taken with or without food. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include headache, tiredness, muscle or joint pain, diarrhea, nausea, bruising, and increased risk of infections. A few patients can undergo severe side effects, including severe bleeding, serious infections, heart rhythm problems such as atrial fibrillation or flutter, and low blood cell counts. Most of the Acalabrutinib 100mg Capsule side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

Avoid grapefruit and grapefruit juice unless your doctor advises. The medicine may harm an unborn baby and should not be used during pregnancy. Women who can become pregnant should use effective contraception during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Acalabrutinib 100mg Capsule must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Head and neck cancer, kidney cancer, lung cancer, liver cancer, skin cancer

The human body shows undesired symptoms after taking Acaluxen 100mg Capsule. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable. Some of the common side effects of Acaluxen Capsule (Acalabrutinib) are mentioned below:
● Fatigue
● Nausea
● Diarrhea
● Headache
● Rash or itching
● Muscle and joint pain
● Bruising or bleeding easily
● Upper respiratory tract infection

Acalabrutinib 100mg Capsule (Acaluxen) is a prescription-based anticancer drug that should be administered orally. It is advised to take this capsule after consulting your healthcare expert. This capsule should be swallowed as a whole with water. Don't crush, chew, or break it. It can be taken with or without food. Never skip a dose or double dose.

Instructions if you miss a dose

● Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., ... & Jurczak, W. (2018). Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. The Lancet, 391(10121), 659-667.
● Byrd, J. C., Woyach, J. A., Furman, R. R., Martin, P., O’Brien, S., Brown, J. R., ... & Wierda, W. G. (2021). Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 137(24), 3327-3338.
● Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., ... & Furman, R. R. (2016). Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374(4), 323-332.
● Markham, A., & Dhillon, S. (2018). Acalabrutinib: first global approval. Drugs, 78(1), 139-145.
● Wu, J., Zhang, M., & Liu, D. (2016). Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. Journal of hematology & oncology, 9(1), 21.